Pulmonx Corp (LUNG) Form 10-Q — Nov 3, 2026
Pulmonx returned to Q3 revenue growth, up 6.2% year-over-year to $22.8 million, driven by higher Zephyr Valve procedure volumes in the US. Nine-month revenue still declined 2.5% to $66.2 million, hurt by lower US volumes and a China pause pending registration renewal, which was secured in June 2026. The net loss narrowed sharply to $8.4 million in Q3 from $14.0 million a year ago, helped by a 21.8% cut in SG&A to $20.0 million and gross margin expansion to 76.2%. Cost discipline was the main driver rather than top-line acceleration.
Key figures
- Revenue
- 22835000
- Total Debt
- 37712000
- Revenue Yoy
- 6.2% (Q3); -2.5% for nine months
- Total Assets
- 110212000
- Cash Position
- 52690000
- Shares Outstanding
- 43550665
- Sga change q3
- -21.8%
- Us revenue q3
- 14911000
- Gross margin q3
- 76.2%
- Accumulated deficit
- 553686000
- Gross margin nine months
- 77.3%
- Perceptive loan effective rate
- 14.0%
- Stock price used in warrant valuation
- 1.53
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.